Gynecologic Oncology

Black women at risk for endometrial cancer favor biopsy-first approaches when provided education, trust, and shared decision-making.

Women with a history of cervical cancer face nearly double the risk of anal cancer, highlighting the need for tailored screening guidelines.

Counties with persistently low cervical cancer screening rates have nearly double the rates of late-stage diagnoses and mortality, study finds.

A new study shows that a self-collected cervical cancer screening device is highly accurate, easy to use, and preferred over clinician collection.

A comparison of 4 ultrasound-based algorithms demonstrated strong performance, with nuanced implications for clinical practice, according to a new study presented at the 2025 ACOG ACSM.

A new study found that while cervical cancer risks remain low for women who meet screening exit criteria, they increase with age and time since last screening.

A new study highlights that sentinel lymph node mapping poses a low risk of lymphedema in women with low-grade endometrial cancer, supporting its use for accurate surgical staging.

A new study reveals that robotic-assisted laparoscopy surgery offers a slight overall survival advantage over conventional laparoscopy surgery for endometrial cancer patients.

Vvax001, a new HPV16 vaccine, offers a potential alternative to surgery for treating precancerous cervical lesions, with promising trial results.

Myriad Genetics' study shows online tools boost hereditary cancer testing rates, improving patient identification, education, and clinician confidence.

A novel ultrasound-based diagnostic algorithm with 98.1% sensitivity enables accurate stratification of patients with mesenchymal uterine malignancies, paving the way for personalized care.

A recent study highlights the growing adoption of less invasive and organ-preserving techniques in gynecologic oncology, with promising implications for patient care.

In a recent study, the prevalence of gynecological cancer trials was reduced in states with high economic vulnerability and minoritized populations.

A recent study shows a significant decrease in primary cytoreductive surgery utilization for advanced ovarian cancer, as neoadjuvant chemotherapy followed by interval cytoreductive surgery gains acceptance for its noninferior survival outcomes and reduced postoperative morbidity.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

In a recent study, patients with a positive response to the Seven-Question Family History Questionnaire were more likely to present with a pathogenic or likely pathogenic variant in the BRCA1 and BRCA2 genes.

In a recent study, a significant improvement in the average quality-adjusted life years gained was reported following BRCA1 testing during obstetrical prenatal carrier screening.

In a recent study, women overdue for cervical cancer and colorectal cancer screening were more likely to receive coverage when offered during their breast cancer screening visit.

A CDC report shows varying HPV vaccination rates in US-affiliated Pacific Islands, with only some regions on track to meet the 2030 WHO goal.

A recent study found that 37% of women do not recognize postmenopausal bleeding as an early symptom of endometrial cancer, indicating a lack of knowledge among patients and providers.

A recent study reported an increase in cervical cancer screening rates among people living with HIV when offering a directed initiative alongside standard care, from 54% to 75%.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Women with ovarian endometriomas or deep infiltrating endometriosis face a significantly higher risk of ovarian cancer, highlighting the need for increased awareness and research into these associations.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.